Male Breast Cancer Terminated Phase 2 Trials for Pazopanib (DB06589)

IndicationStatusPhase
DBCOND0028546 (Male Breast Cancer)Terminated2
clinicaltrials.gov IdentifierTitlePurposeDrugs
NCT01394211Neo-adjuvant Therapy With Anastrozole Plus Pazopanib in Stage II and III ER+ Breast CancerTreatment